{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:48:37Z","timestamp":1785757717410,"version":"3.56.0"},"reference-count":88,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Mark. Access Health Policy","JMAHP"],"abstract":"<jats:p>Background: The EU Health Technology Assessment Regulation (EU-HTA R), effective January 2025, mandates Joint Clinical Assessments (JCAs) to harmonize HTA across Member States. However, its implementation raises fundamental questions about methodological coherence, institutional capacity, and epistemological alignment. Objectives: This manuscript (1) systematically assesses whether the stated strategic and operational objectives of the EU-HTA R are achievable under current implementation conditions; (2) examines the implications for EU institutional legitimacy if these objectives are not met; and (3) proposes an epistemological framework as a prerequisite for developing a coherent joint HTA methodology. Methods: We conducted a critical policy analysis of the EU-HTA R, its implementing guidance documents, and published templates, supplemented by a comparative review of Member State HTA methodologies and their underlying philosophical foundations. Results: The analysis reveals that the EU-HTA R is unlikely to achieve its strategic goals under current conditions. Key findings include: guidance documents of substandard methodological quality; a restricted assessment scope that excludes scientific judgement and contextualization; insufficient resources and additional workload for national HTA bodies without reducing existing obligations; unresolved epistemological divergences among Member States spanning Bayesian vs. frequentist approaches, Fisher vs. Neyman\u2013Pearson frameworks, and utilitarian vs. deontological ethical foundations; and procedural shortcomings in stakeholder consultation and expert involvement. These shortcomings risk undermining the epistemic authority and legitimacy of EU institutions. Conclusions: Prior epistemological and normative alignment across Member States is a prerequisite for any robust shared HTA methodology. Revisions to the EU-HTA R and comprehensive updates of guidance documents are necessary, with concrete safeguards\u2014including independent peer review, identified authorship, and adequate resourcing\u2014to ensure substantive rather than merely nominal implementation. A phased roadmap is proposed: establishing clear objectives, aligning epistemological foundations, developing institutional structures, and creating operationally consistent guidance.<\/jats:p>","DOI":"10.3390\/jmahp14030045","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:24:07Z","timestamp":1785752647000},"page":"45","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The European Union\u2019s Health Technology Assessment Regulation (EU-HTA R) Will Prosper Despite Major Setbacks"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7939-7204","authenticated-orcid":false,"given":"Mondher","family":"Toumi","sequence":"first","affiliation":[{"name":"CEReSS\/UR3279\u2014Health Services Research and Quality of Life Center, Aix-Marseille University, 13385 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imen","family":"Soussi","sequence":"additional","affiliation":[{"name":"Clever Access, Tunis 1058, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Falissard","sequence":"additional","affiliation":[{"name":"CESP, INSERM U1018, Universit\u00e9 Paris-Saclay, 94800 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9512-2005","authenticated-orcid":false,"given":"Steven","family":"Simoens","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3595-6303","authenticated-orcid":false,"given":"Asma","family":"Jouini","sequence":"additional","affiliation":[{"name":"Clever Access, Tunis 1058, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Postma","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University Medical Center Groningen, University of Groningen, 9700 AB Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9653-168X","authenticated-orcid":false,"given":"Juergen","family":"Wasem","sequence":"additional","affiliation":[{"name":"Faculty for Economics and Business Administration, Institute for Health Care Management and Research, University Duisburg-Essen, 45127 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8312-8178","authenticated-orcid":false,"given":"Oriol","family":"Sol\u00e0-Morales","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 HiTT, Arag\u00f3 60, Pral. 1a, 08015 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1229-6622","authenticated-orcid":false,"given":"Laurent","family":"Boyer","sequence":"additional","affiliation":[{"name":"CEReSS\/UR3279\u2014Health Services Research and Quality of Life Center, Aix-Marseille University, 13385 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Dussart","sequence":"additional","affiliation":[{"name":"UR 4129 P2S Parcours Sant\u00e9 Syst\u00e9mique, Universit\u00e9 Claude Bernard Lyon 1, 7-11 Rue Guilllaume Paradin, 69008 Lyon, France"},{"name":"Pharmacie Centrale, Hospices Civils de Lyon, 57 Rue Francisque Darcieux, Saint-Genis-Laval, 69230 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1711-0284","authenticated-orcid":false,"given":"Borislav","family":"Borissov","sequence":"additional","affiliation":[{"name":"Department HTA, Faculty of Public Health, Medical University of Sofia, 1527 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Bernardini","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences (BIOMETEC), Section of Pharmacology, University of Catania, 95124 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4633-4420","authenticated-orcid":false,"given":"Stefano","family":"Capri","sequence":"additional","affiliation":[{"name":"School of Economics and Management, Cattaneo-LIUC University, 21053 Castellanza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7299-6554","authenticated-orcid":false,"given":"Jaime","family":"Espin","sequence":"additional","affiliation":[{"name":"Andalusian School of Public Health\/Escuela Andaluza de Salud P\u00fablica (EASP), 18011 Granada, Spain"},{"name":"CIBER en Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP)\/CIBER of Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria ibs.GRANADA, 18012 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3496-1996","authenticated-orcid":false,"given":"Pascal","family":"Auquier","sequence":"additional","affiliation":[{"name":"CEReSS\/UR3279\u2014Health Services Research and Quality of Life Center, Aix-Marseille University, 13385 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"ref_1","unstructured":"(2025, February 10). Official Journal of the European Union: Options for Improving Access to Medicines. Available online: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:52017IP0061."},{"key":"ref_2","unstructured":"(2025, February 10). Official Journal of the European Union: Regulation (EU) 2021\/2282 of the European Parliament and of the Council of 15 December 2021 on Health Technology Assessment and Amending Directive 2011\/24\/EU 2021. Available online: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32021R2282."},{"key":"ref_3","unstructured":"(2025, February 10). Official Journal of the European Union: Directive 2011\/24\/EU of the European Parliament and of the Council of 9 March 2011 on the Application of Patients\u2019 Rights in Cross-Border Healthcare. Available online: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32011L0024."},{"key":"ref_4","unstructured":"European Commission, Directorate-General for Health and Food Safety, Gesundheit \u00d6sterreich Forschungs- und Planungs GmbH, The London School of Economics and Political Science, and SOGETI (2018). Study on Impact Analysis of Policy Options for Strengthened EU Cooperation on Health Technology Assessment (HTA)\u2014Final Report, Publications Office of the European Union."},{"key":"ref_5","unstructured":"European Federation of Pharmaceutical Industries and Associations (2024). EFPIA Patients W.A.I.T. Indicator 2023 Survey, European Federation of Pharmaceutical Industries and Associations. Available online: https:\/\/efpia.eu\/media\/vtapbere\/efpia-patient-wait-indicator-2024.pdf."},{"key":"ref_6","unstructured":"European Federation of Pharmaceutical Industries and Associations (EFPIA) (2025, February 10). The Root Cause of Unavailability and Delay to Innovative Medicines: Reducing the Time Before Patients Have Access to Innovative Medicines. Available online: https:\/\/www.efpia.eu\/media\/636822\/root-cause-unavailability-delays-cra-report-april-2022-final.pdf."},{"key":"ref_7","unstructured":"European Federation of Pharmaceutical Industries and Associations (EFPIA) (2025, February 11). The Root Causes of Unavailability of Innovative Medicines and Delay in Access: Shortening the Wait. Available online: https:\/\/efpia.eu\/media\/xsmfuf4h\/root-causes-of-unavailability-and-delay-efpia-cra-2024.pdf."},{"key":"ref_8","unstructured":"European Federation of Pharmaceutical Industries and Associations (EFPIA) (2025, February 12). European Access Hurdles Portal: Results from the Second Year of Data Collection. Available online: https:\/\/efpia.eu\/media\/0m4pswzd\/european-access-hurdles-portal-2024-cra-report.pdf."},{"key":"ref_9","unstructured":"European Federation of Pharmaceutical Industries and Associations (EFPIA) (2025, February 11). Addressing Patient Access Inequalities in Europe. The Industry Commitment to File Pricing and Reimbursement Applications Across Europe and the European Access Portal. Available online: https:\/\/www.efpia.eu\/media\/677156\/addressing-patient-access-inequalities-in-europe.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3389\/fphar.2017.00384","article-title":"A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?","volume":"8","author":"Allen","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_11","unstructured":"Szerb, A., and Kanavos, P. (2015). Health Technology Assessment of Cancer Drugs in France and Germany: Commonalities and Differences in the Value Assessment of Medical Technologies, LSE Health. Available online: https:\/\/www.lse.ac.uk\/lse-health\/assets\/documents\/working-paper-series\/LSEHWP43.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/cer-2021-0047","article-title":"Health technology assessment (HTA) in England, France and Germany: What do matched drug pairs tell us about recommendations by national HTA agencies?","volume":"10","author":"Schaefer","year":"2021","journal-title":"J. Comp. Eff. Res."},{"key":"ref_13","unstructured":"Zamora, B., Maignen, F., O\u2019Neill, P., Mestre-Ferrandiz, J., and Garau, M. (2017). Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and Other European Countries, OHE Consulting. Available online: https:\/\/www.ohe.org\/wp-content\/uploads\/2017\/03\/Access-to-OMPs-Report.pdf."},{"key":"ref_14","first-page":"e50560","article-title":"Appraisal of Novel Oncological Therapies by the Scottish Medicines Consortium and the National Institute for Health and Care Excellence: A Comparative Study of Six Years of Data","volume":"15","author":"Taylor","year":"2023","journal-title":"Cureus"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"A347","DOI":"10.1016\/j.jval.2016.09.008","article-title":"Aligned and Flexible? A Comparative Review of SMC and Nice Decision-Making","volume":"19","author":"Johnson","year":"2016","journal-title":"Value Health"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"22S8610","DOI":"10.1016\/j.jval.2019.09.2439","article-title":"A Comparative Review of NICE and SMC Decision-Making for Ultra-Orphan Medicines","volume":"22","author":"Gibbs","year":"2019","journal-title":"Value Health"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1017\/S026646232300048X","article-title":"Do France, Germany, and Italy agree on the added therapeutic value of medicines?","volume":"39","author":"Casilli","year":"2023","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_18","unstructured":"(2025, February 16). The German\u2019s Social Code V\u2013Statutory Health Insurance (Sozialgesetzbuch F\u00fcnftes Buch\u2014Gesetzliche Krankenversicherung). Available online: https:\/\/www.gesetze-im-internet.de\/sgb_5\/."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1369817","DOI":"10.1080\/20016689.2017.1369817","article-title":"The perverse impact of external reference pricing (ERP): A comparison of orphan drugs affordability in 12 European countries. A call for policy change","volume":"5","author":"Young","year":"2017","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_20","unstructured":"Kanavos, P.G., Vandoros, S., Irwin, R.E., Nicod, E., and Casson, M. (2010). Differences in costs of and access to pharmaceutical products in the EU2011: Directorate general for internal policies, Policy Department A: Economic and Scientific Policy."},{"key":"ref_21","unstructured":"European Commission, Gesundheit \u00d6sterreich Forschung- und Planungs GmbH Publications, Vogler, S., Lepusch\u00fctz, L., Schneider, P., and St\u00fchlinger, V. (2015). Study on Enhanced Cross-Country Coordination in the Area of Pharmaceutical Product Pricing, Publications Office of the European Union. Final Report."},{"key":"ref_22","unstructured":"European Commission (2025, February 17). Commission Proposes Critical Medicines Act to Bolster the Supply of Critical Medicines in the EU, Available online: https:\/\/ec.europa.eu\/commission\/presscorner\/api\/files\/document\/print\/en\/ip_25_733\/IP_25_733_EN.pdf."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Desmet, T., Brijs, M., Vanderdonck, F., Tops, S., Simoens, S., and Huys, I. (2024). Implementing the EU HTA regulation: Insights from semi-structured interviews on patient expectations, Belgian and European institutional perspectives, and industry outlooks. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1369508"},{"key":"ref_24","first-page":"50","article-title":"Forging a European Health Union: Between subsidiarity and sovereignty?","volume":"28","author":"Kuiper","year":"2022","journal-title":"EuroHealth"},{"key":"ref_25","unstructured":"(2025, February 17). European Parliament. Directorate General For Research. Health Care Systems in Europe. A Comparative Study. Working Paper. Public Health and Consumer Protection Series. SACO 101. Available online: https:\/\/www.europarl.europa.eu\/workingpapers\/saco\/pdf\/101_en.pdf."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ndt\/14.suppl_6.3","article-title":"Healthcare systems\u2014An international review: An overview","volume":"14","author":"Lameire","year":"1999","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/09720634231153215","article-title":"Does the Type of Healthcare Financing Systems Matter for Efficiency?","volume":"25","author":"Shufani","year":"2023","journal-title":"J. Health Manag."},{"key":"ref_28","unstructured":"European Commission (2025, February 19). Proposal for a Directive of the European Parliament and of the Council on the Union Code Relating to Medicinal Products for Human Use, Available online: https:\/\/eur-lex.europa.eu\/resource.html?uri=cellar:e3f40e76-e437-11ed-a05c-01aa75ed71a1.0001.02\/DOC_1&format=PDF."},{"key":"ref_29","unstructured":"European Commission (2025, February 19). Factsheet\u2014Critical Medicines Act: Improving the Availability and Securing Supply of Critical Medicines in the EU. Available online: https:\/\/health.ec.europa.eu\/document\/download\/cd85a596-20b2-47a2-9a03-4fdcb24f9f7b_en?filename=mp_mca_supply_factsheet_en.pdf."},{"key":"ref_30","unstructured":"(2025, February 25). EFPIA Response to the Critical Medicines Act. Available online: https:\/\/www.efpia.eu\/news-events\/the-efpia-view\/statements-press-releases\/efpia-response-to-the-critical-medicines-act\/."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/00019053-199813030-00001","article-title":"The Pros and Cons of a Single \u2018Euro\u2014Price\u2019 For Drugs","volume":"13","author":"Towse","year":"1998","journal-title":"PharmacoEconomics"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Zaprutko, T., Kopciuch, D., Kus, K., Merks, P., Nowicka, M., Augustyniak, I., and Nowakowska, E. (2017). Affordability of medicines in the European Union. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0172753"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Lepage-Nefkens, I., Douw, K., Mantjes, G., de Graaf, G., Leroy, R., and Cleemput, I. (2017). Horizon Scanning for Pharmaceuticals: Proposal for the BeNeLuxA Collaboration, Belgian Health Care Knowledge Centre (KCE). Available online: https:\/\/kce.fgov.be\/sites\/default\/files\/2021-11\/Horizon%20scanning_ScientificReport_.pdf.","DOI":"10.57598\/R283C"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Toumi, M., Fallissard, B., Jouini, A., Auquier, P., Dussart, C., and Boyer, L. (2025). Guidance on Multiplicity Analysis in Single-Trial Assessments: A No-Solution Equation. Preprints, 2025042463.","DOI":"10.20944\/preprints202504.2463.v1"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Aball\u00e9a, S., Toumi, M., Wojciechowski, P., Clay, E., Falissard, B., Simoens, S., Auquier, P., Capri, S., Bernardini, R., and Ruof, J. (2026). Between Rigor and Relevance: Why the EU HTA Guidelines on Indirect Comparisons Miss the Mark. J. Mark. Access Health Policy, 14.","DOI":"10.3390\/jmahp14020030"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Smela, B., Toumi, M., Aball\u00e9a, S., Simoens, S., Boyer, L., Falissard, B., Bernardini, R., Capri, S., and Auquier, P. (2026). The EU-Joint Clinical Assessment Guidance Documents Fail to Address the Significance of Systematic Literature Reviews and Deviate from the State of the Art. J. Mark. Access Health Policy, 14.","DOI":"10.3390\/jmahp14030037"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Toumi, M., Falissard, B., Jouini, A., Aball\u00e9a, S., and Boyer, L. (2025). Clinical Trial Validity Guidance from the HTACG: Looking for Chicken Teeth. J. Mark. Access Amp Health Policy, 13.","DOI":"10.3390\/jmahp13020015"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1136\/bmj.319.7225.1618","article-title":"Seven alternatives to evidence based medicine","volume":"319","author":"Isaacs","year":"1999","journal-title":"BMJ"},{"key":"ref_39","unstructured":"European Access Academy (2025, February 26). Open Letter from the EAA Faculty to the HTACG and DG Sant\u00e9 on the EU HTA Methods Guidance Documents. Available online: https:\/\/irp.cdn-website.com\/e52b6f19\/files\/uploaded\/Open_Letter_Methods_EU_HTA.pdf."},{"key":"#cr-split#-ref_40.1","unstructured":"European Commission (2025, February 27). Guidance on Validity of Clinical Studies. V1.0. Adopted on 19 September 2024 by the HTA CG Pursuant to Article 3(7), Point (d), of Regulation"},{"key":"#cr-split#-ref_40.2","unstructured":"(EU) 2021\/2282 on Health Technology Assessment. Available online: https:\/\/health.ec.europa.eu\/document\/download\/9f9dbfe4-078b-4959-9a07-df9167258772_en?filename=hta_clinical-studies-validity_guidance_en.pdf."},{"key":"#cr-split#-ref_41.1","unstructured":"European Commission (2025, February 26). Guidance on Reporting Requirements for Multiplicity Issues and Subgroup, Sensitivity and Post Hoc Analyses in Joint Clinical Assessments. Adopted on 10 June 2024 by the HTA CG Pursuant to Article 3(7), Point (d), of Regulation"},{"key":"#cr-split#-ref_41.2","unstructured":"(EU) 2021\/2282 on Health Technology Assessment. Available online: https:\/\/health.ec.europa.eu\/document\/download\/f2f00444-2427-4db9-8370-d984b7148653_en?filename=hta_multiplicity_jca_guidance_en.pdf."},{"key":"ref_42","unstructured":"European Commission (2025, March 04). EU HTA Regulation for Health Technology Developers. HTD\/SME Webinar. Available online: https:\/\/health.ec.europa.eu\/document\/download\/591a434a-bb14-4dd7-a3c4-bca29077289d_en?filename=hta_20250124_pres01_en.pdf."},{"key":"ref_43","unstructured":"Cervelo Bouzo, P., Wang, T., Lara, J., and McAuslane, N. (2024). Frequency and Variation of Clock-Stop During EMA Assessment for Oncology Products: Implication on JCA Timelines, ISPOR Europe. Available online: https:\/\/www.ispor.org\/docs\/default-source\/euro2024\/isporeurope24cervelobouzohpr86poster144868-pdf.pdf?sfvrsn=ebd2a543_0."},{"key":"ref_44","unstructured":"Griffin, A. (2025, February 24). JCA Timeline Under the Standard EMA Process Using a Day 120 Clock Stop Duration of 1 Month (31 Days) [LinkedIn Post]. Available online: https:\/\/www.linkedin.com\/feed\/update\/urn:li:activity:7183712862220001281\/."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e240179","DOI":"10.57264\/cer-2024-0179","article-title":"Access in all areas? A round up of developments in market access and health technology assessment: Part 4","volume":"13","author":"Beattie","year":"2024","journal-title":"J. Comp. Eff. Res."},{"key":"ref_46","unstructured":"PICO (2025, February 26). Exercise MP 01: Durvalumab (Imfinzi\u00ae) for Adults with Advanced or Unresectable Hepatocellular Carcinoma (HCC). Available online: https:\/\/health.ec.europa.eu\/document\/download\/322ae969-f3ca-4f23-ab8e-1b4bdf22528f_en?filename=hta_pico_mp01_en_0.pdf."},{"key":"ref_47","unstructured":"PICO (2025, February 24). Exercise MP 03: Adagrasib (Krazati\u00ae) for Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation After Disease Progression Following Prior Systemic Therapy. Available online: https:\/\/health.ec.europa.eu\/document\/download\/63868893-b079-4ea6-bf94-af2cd9f19c65_en?filename=hta_pico_mp03_en_0.pdf."},{"key":"ref_48","unstructured":"European Federation of Pharmaceutical Industries and Associations (EFPIA) (2025, March 04). EU HTA Regulation for Oncology Medicines: Learnings from a Simulation on the Impact of Proposed EUnetHTA21 Methods. Available online: https:\/\/www.efpia.eu\/media\/qrjah2ij\/efpia-evidera-research-on-eunethta21-methods.pdf."},{"key":"ref_49","unstructured":"Leemans, J., Meijns, B., and Boodts, S. (2016). What is epistemic authority? A model and some examples from ancient philosophy. Shaping Authority How Did a Person Become an Authority in Antiquity, the Middle Ages and the Renaissance?, Brepols."},{"key":"ref_50","unstructured":"Baril, A. (2013). Review of Epistemic Authority: A Theory of Trust, Authority, and Autonomy in Belief, by L. T. Zagzebski. Notre Dame Philos. Rev., Available online: https:\/\/ndpr.nd.edu\/reviews\/epistemic-authority-a-theory-of-trust-authority-and-autonomy-in-belief\/."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/0002764209338797","article-title":"Conceptualizing Legitimacy, Measuring Legitimating Beliefs","volume":"53","author":"Levi","year":"2009","journal-title":"Am. Behav. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1080\/13501763.2011.593309","article-title":"Regulatory networks and regulatory agencification: Towards a single European regulatory space","volume":"18","year":"2011","journal-title":"J. Eur. Public Policy"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/01402389408425031","article-title":"The rise of the regulatory state in Europe","volume":"17","author":"Majone","year":"1994","journal-title":"West Eur. Politics"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Hodson, D., Puetter, U., Saurugger, S., and Peterson, J. (2021). European Union agencies: Explaining EU agency behaviour, processes, and outputs. The Institutions of the European Union, Oxford University Press. [5th ed.].","DOI":"10.1093\/hepl\/9780198862222.001.0001"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1080\/13501763.2023.2173274","article-title":"Regulatory cybersecurity governance in the making: The formation of ENISA and its struggle for epistemic authority","volume":"30","author":"Smeets","year":"2023","journal-title":"J. Eur. Public Policy"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/13501763.2023.2172061","article-title":"The regulatory security state in Europe","volume":"30","author":"Kruck","year":"2023","journal-title":"J. Eur. Public Policy"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1080\/13501763.2023.2172060","article-title":"The (False) promise of solutionism: Ideational business power and the construction of epistemic authority in digital security governance","volume":"30","author":"Obendiek","year":"2023","journal-title":"J. Eur. Public Policy"},{"key":"ref_58","unstructured":"Draghi, M. (2025, March 04). The Future of European Competitiveness: Part B\u2014In-Depth Analysis and Recommendations, Available online: https:\/\/commission.europa.eu\/document\/download\/ec1409c1-d4b4-4882-8bdd-3519f86bbb92_en?filename=The%20future%20of%20European%20competitiveness_%20In-depth%20analysis%20and%20recommendations_0.pdf."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"27S305","DOI":"10.1016\/j.jval.2024.10.1578","article-title":"HPR152. A Comparison of the Acceptability of Evidence in the New Joint Clinical Assessment and Nine European Union Countries","volume":"27","author":"Lambert","year":"2024","journal-title":"Value Health"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e240240","DOI":"10.57264\/cer-2024-0240","article-title":"Mapping methods gaps between EU joint clinical assessments and local health technology assessment decision-making: An environmental scan of guidance in select EU markets and harmonization challenges","volume":"14","author":"Sarri","year":"2025","journal-title":"J. Comp. Eff. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/14737167.2023.2263166","article-title":"Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies\u2014Can alignment be improved?","volume":"24","author":"Wolters","year":"2024","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"ref_62","first-page":"399","article-title":"Efficiency of healthcare systems in the European Union states\u2014Who performs better\u2014Bismarckians or Beveridgeans?","volume":"XXIV","author":"Zdrazil","year":"2021","journal-title":"Eur. Rev. Soc. Sci."},{"key":"ref_63","unstructured":"Strohmaier, C., and Zechmeister-Koss, I. (2024). Threshold Values in Health Economic Evaluations and Decision-Making, HTA Austria\u2014Austrian Institute for Health Technology Assessment GmbH. Available online: https:\/\/eprints.aihta.at\/1549\/1\/HTA-Projektbericht_Nr.163.pdf."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4103\/2229-5070.175024","article-title":"Utilitarian and deontological ethics in medicine","volume":"6","author":"Mandal","year":"2016","journal-title":"Trop. Parasitol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Bloemen, B., Oortwijn, W., and van der Wilt, G.J. (2024). Understanding the Normativity of Health Technology Assessment: Ontological, Moral, and Epistemological Commitments. Health Care Anal., online ahead of print.","DOI":"10.1007\/s10728-024-00487-x"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.ijrobp.2021.12.011","article-title":"Understanding the Differences Between Bayesian and Frequentist Statistics","volume":"112","author":"Mistry","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0140-6736(24)01295-9","article-title":"Bayesian statistics for clinical research","volume":"404","author":"Goligher","year":"2024","journal-title":"Lancet"},{"key":"ref_68","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (2025, March 05). Transparency Committee Doctrine. Principles of Medicinal Product Assessments and Appraisal for Reimbursement Purposes. Available online: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2019-07\/doctrine_de_la_commission_de_la_transparence_-_version_anglaise.pdf."},{"key":"ref_69","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG) (2023). General Methods, IQWiG. Available online: https:\/\/www.iqwig.de\/methoden\/general-methods_version-7-0.pdf."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e091961","DOI":"10.1136\/bmjopen-2024-091961","article-title":"Selection of indirect treatment comparisons for health technology assessments: A practical guide for health economics and outcomes research scientists and clinicians","volume":"15","author":"Guo","year":"2025","journal-title":"BMJ Open"},{"key":"ref_71","unstructured":"Phillippo, D.M., Ades, A.E., Dias, S., Palmer, S., Abrams, K.R., and Welton, N. (2025, March 10). NICE DSU Technical Support Document 18: Methods for Population-Adjusted Indirect Comparisons in Submission to NICE. Available online: https:\/\/research-information.bris.ac.uk\/ws\/portalfiles\/portal\/94868463\/Population_adjustment_TSD_FINAL.pdf."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200624010-00001","article-title":"Bayesian methods for evidence synthesis in cost-effectiveness analysis","volume":"24","author":"Ades","year":"2006","journal-title":"PharmacoEconomics"},{"key":"ref_73","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG) (2025). General Methods: Draft Version 8.0. (German Version 25.02.2025), IQWiG. Available online: https:\/\/www.iqwig.de\/methoden\/allgemeine-methoden_entwurf-fuer-version-8-0.pdf."},{"key":"ref_74","unstructured":"Yu, C.-H. (2025, March 11). Balkanization and Unification of Probabilistic Inferences, Available online: https:\/\/eric.ed.gov\/?id=ED490344."},{"key":"ref_75","first-page":"21","article-title":"P-value, a true test of statistical significance? A cautionary note","volume":"6","author":"Dahiru","year":"2008","journal-title":"Ann. Ib. Postgrad. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s11999-009-1164-4","article-title":"P value and the theory of hypothesis testing: An explanation for new researchers","volume":"468","author":"Biau","year":"2010","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1080\/01621459.1993.10476404","article-title":"The Fisher, Neyman-Pearson Theories of Testing Hypotheses: One Theory or Two?","volume":"88","author":"Lehmann","year":"1993","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_78","unstructured":"National Institute for Health and Care Excellence (2025, March 12). Developing NICE Guidelines: The Manual. NICE Process and Methods. Reference Number: PMG20. Available online: https:\/\/www.nice.org.uk\/process\/pmg20."},{"key":"ref_79","unstructured":"The German Federal Joint Committee (G-BA) (2025, March 13). Rules of Procedure of the Federal Joint Committee. Available online: https:\/\/www.g-ba.de\/richtlinien\/42\/."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1017\/S026646230300028X","article-title":"Health technology assessment: The contribution of qualitative research","volume":"19","author":"Leys","year":"2003","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_81","unstructured":"Broom, A., and Willis, E. (2007). Competing Paradigms and Health Research. Researching Health: Qualitative, Quantitative and Mixed Methods, Sage."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cTo whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/bmj.325.7378.1437","article-title":"Data dredging, bias, or confounding","volume":"325","author":"Smith","year":"2002","journal-title":"BMJ"},{"key":"ref_84","unstructured":"Morey-Vargas, O.L., Zeballos-Palacios, C., Gionfriddo, M.R., and Montori, V.M. (2014). The hierarchy of evidence. Network Meta-Analysis: Evidence Synthesis with Mixed Treatment Comparison, Nova Science Publishers, Inc."},{"key":"ref_85","unstructured":"Bertram, M., Dhaene, G., and Tan-Torres Edejer, T. (2021). Institutionalizing Health Technology Assessment Mechanisms: A How to Guide, World Health Organization. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/340722\/9789240020665-eng.pdf?sequence=1."},{"key":"ref_86","unstructured":"European Commission (2025, March 13). Commission Staff Working Document: Impact Assessment\u2014Strengthening of the EU Cooperation on Health Technology Assessment (HTA): Accompanying the Document Proposal for a Regulation of the European Parliament and of the Council on Health Technology Assessment and Amending Directive 2011\/24\/EU, Available online: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:52018SC0041."}],"container-title":["Journal of Market Access &amp; Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2001-6689\/14\/3\/45\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:26:17Z","timestamp":1785756377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2001-6689\/14\/3\/45"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":88,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jmahp14030045"],"URL":"https:\/\/doi.org\/10.3390\/jmahp14030045","relation":{},"ISSN":["2001-6689"],"issn-type":[{"value":"2001-6689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}